A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Clinical Pharmacology and Therapeutics
DOIs	https://doi.org/10.1038/clpt.2011.303
Publication status	Published - 28 Mar 2012

Access to Document

@article{92df42054cb4486e9bb825a6a133d9b8,

title = "A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention",

author = "D. Hughes and G.F. Guzauskas and D.A. Hughes and S.M. Bradley and D.L. Veenstra",

year = "2012",

month = mar,

day = "28",

doi = "10.1038/clpt.2011.303",

language = "English",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

AU - Hughes, D.

AU - Guzauskas, G.F.

AU - Hughes, D.A.

AU - Bradley, S.M.

AU - Veenstra, D.L.

PY - 2012/3/28

Y1 - 2012/3/28

U2 - 10.1038/clpt.2011.303

DO - 10.1038/clpt.2011.303

M3 - Article

SN - 0009-9236

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

ER -